I looked at PGNX old PR's and they do not state P values in the couple I saw so probably I am making too much out of it.
I would still like to see the full dataset to compare. If the oral data is comparable to the sub-q then I don't see any huge competitive advantage (for either company). One thing to Keep in mind is AstraZenca is running trials in multiple patient populations and so could get a broader label (if the drug is eventually approved).
My comment earlier to vinmantoo was about it chronic use of the drug in general. I got the impression you take the drug each time you want to go and it works within 4 hours or so (if its going to work). As opposed to Nektar's drug which is intended to offset the constipation side-effects of the opioids and make the person more regular in general. Perhaps a subtle but to me a very important distinction.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.